Answers are grounded in this paper and cite their sources.
Background Anticipatory injectable medications for symptom control are a key end-of-life care intervention internationally. Research has focused largely on the perspectives of doctors and nurses, with limited understanding of the wider stakeholder network involved in community-based systems for using anticipatory injectable medications. This study aimed to identify the needs and priorities of a wide range of stakeholders involved in their use in community-based systems. Methods We adopted a qualitative exploratory design, using an UK-wide online survey between September and October 2024. Participants provided anonymised demographic information and completed up to four prompts capturing their: stakeholder role (as a…): needs (I need...), and priorities (so that…). Data were analysed using a combined inductive–deductive framework to produce shortlists of stakeholder priorities and needs. Results In total, 439 participants contributed 729 responses across multiple stakeholder groups. Findings revealed substantial diversity in stakeholder needs and priorities, both within and between groups. Some public and professional stakeholders expressed competing priorities and needs. Most stakeholder groups prioritised timely care, minimising of suffering, and wanted nationally consistent guidance for using injectable medications. Responses also reflected concerns about healthcare resource constraints and the potential implications of assisted dying legislation on systems for using medications. Conclusions Our findings highlight the wide diversity in priorities and needs between stakeholders involved in the use of anticipatory injectable medications. Understanding these differing priorities may support the design of more inclusive and responsive community-based systems for their use.
No takes yet. Share an insight, caveat, or question.
Perera et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: